For foreign patent attorneys managing PCT portfolios, India introduces a procedural element that requires deliberate risk assessment: the pre-grant opposition mechanism. Unlike many jurisdictions where third-party challenges arise only after grant, Indian patent law permits opposition at any time after publication and before the patent is granted. For commercially relevant technologies, this creates a real and measurable exposure during prosecution.
Pre-grant opposition is governed by Section 25(1) of the Patents Act, 1970. Any person may file a representation opposing the grant of a patent after the application is published and before it is granted. The breadth of this provision is significant. The opponent does not need to demonstrate commercial harm or standing in the traditional sense. Competitors, industry participants, or even public interest groups may initiate proceedings.
In the context of PCT national phase applications, timing becomes important. Once the international application enters India and is published in the Indian Patent Office database, the window for pre-grant opposition opens and remains active until grant. This means that even after a favorable response to a First Examination Report, and even when the application appears close to allowance, a third-party intervention may alter the prosecution trajectory.
The statutory grounds for pre-grant opposition broadly reflect invalidity grounds familiar in other jurisdictions. These include lack of novelty, lack of inventive step, non-patentable subject matter, insufficient disclosure, wrongful obtaining, and failure to comply with disclosure requirements such as those under Section 8. In practice, certain grounds are more frequently invoked in national phase matters. Inventive step challenges supported by multiple prior art combinations are common. In pharmaceutical and chemical cases, objections under Section 3(d) are routinely raised. In software and AI-related applications, subject matter exclusions under Section 3(k) often form part of the opposition strategy. Procedural lapses, particularly incomplete disclosure of foreign filings, are also used tactically.
The practical impact of a pre-grant opposition can be substantial. The proceedings introduce an adversarial dimension into what would otherwise be routine examination. Written submissions become more detailed. Hearings are frequently required. Technical arguments must be supported with clarity and consistency across the specification and claims. The timeline to grant may extend, and prosecution costs inevitably increase.
Not all applications carry the same exposure. The likelihood of opposition tends to correlate with commercial visibility and competitive sensitivity. Applications covering pharmaceutical compounds, medical devices, telecom standards, or high-value platform technologies are more likely to attract scrutiny. A crowded prior art landscape or unusually broad claim scope relative to the disclosure may further increase vulnerability. Where a product is already launched or publicly discussed in the Indian market, the risk profile rises.
For foreign associates considering India at the national phase stage, pre-grant opposition should be part of the initial evaluation. It is prudent to assess whether the specification contains sufficient technical depth to withstand inventive step attacks, whether subject matter exclusions have been adequately addressed in the drafting, and whether procedural compliance has been meticulously maintained. If the original PCT disclosure is thin or heavily functional, strategic claim calibration at the time of entry may reduce exposure.
Pre-grant opposition does not automatically suspend examination. The Controller considers the representation alongside the examination record. In practice, this often results in consolidated hearings where both the applicant and the opponent present arguments. The quality of written advocacy becomes critical. Arguments must address not only statutory objections raised in the First Examination Report but also the technical and legal positions advanced by the opponent.
From a portfolio management perspective, opposition exposure should be weighed against commercial objectives. In some cases, a narrower but defensible claim set may offer greater long-term value than pursuing maximal scope at the risk of prolonged challenge. In others, the commercial importance of the invention may justify a more assertive prosecution strategy despite anticipated opposition.
Pre-grant opposition in India is neither exceptional nor unpredictable. It is an established component of the patent system. For PCT national phase applications of strategic significance, it should be treated as a foreseeable procedural risk. Early technical evaluation, careful claim structuring, and strict procedural compliance materially strengthen defensibility before the Indian Patent Office.
Origiin IP Solutions LLP regularly advises foreign patent attorneys and law firms on opposition risk assessment for India PCT national phase applications and represents applicants in pre-grant opposition proceedings. A structured review at the entry stage can significantly influence prosecution strategy and overall portfolio strength in India.
For strategic assessment of pre-grant opposition exposure and prosecution support for India PCT national phase applications:
https://origiin.com/contact-us/
To understand the India PCT national phase procedure, timelines, and compliance framework in detail:
https://origiin.com/pct-national-phase-entry-india/
